publications-banner

Information about pipeline products

PublicationView

HER3-DXd
Breast Cancer
Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study
Oliveira M, Falato C, Margelí Vila M, et al.
Ann Oncol. 2023;34(8):670-680.
T-DXd
Breast Cancer
Real-world perspectives and practices for pneumonitis/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2-expressing metastatic breast cancer
Rugo HS, Crossno CL, Gesthalter YB, et al.
JCO Oncol Pract. 2023;19(8):539-546.
T-DXd
Breast Cancer
Newly approved and emerging agents in HER2-positive metastatic breast cancer
Graff SL, Yan F, Abdou Y.
Clin Breast Cancer. 2023;23(7):e380-e393.
T-DXd
Breast Cancer
Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study
Curigliano G, Dunton K, Rosenlund M, et al.
Ann Oncol. 2023;34(7):569-77.
Edoxaban
Cardiovascular - AF
Risk of both intracranial hemorrhage and ischemic stroke in elderly individuals with nonvalvular atrial fibrillation taking direct oral anticoagulants compared with warfarin: Analysis of the ANAFIE registry
Shiozawa M, Koga M, Inoue H, et al.
Int J Stroke. 2023;18(8):986-995.
Quizartinib
Hematology
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): A randomised, double-blind, placebo-controlled, phase 3 trial
Erba HP, Montesinos P, Kim HJ, et al.
Lancet. 2023;401(10388):1571-1583.
T-DXd
Breast Cancer
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): A randomised, open-label, multicentre, phase 3 trial
André F, Hee Park Y, Kim SB, et al.
Lancet. 2023;401(10390):1773-1785.
Pexidartinib
Other/Multi
Dosing recommendation based on the effects of different meal types on pexidartinib pharmacokinetics in healthy subjects: Implementation of model-informed drug development strategy
Zahir H, Yin O, Hsu C, et al.
Clin Pharmacol Drug Dev. 2023;12(5):475-483.
Valemetostat
Hematology
An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma
Izutsu K, Makita S, Nosaka K, et al.
Blood. 2023;141(10):1159-1168.
Edoxaban
Cardiovascular - AF
Clinical phenotypes of older adults with non-valvular atrial fibrillation not treated with oral anticoagulants by hierarchical cluster analysis in the ANAFIE registry
Suzuki S, Yamashita T, Akao M, et al.
PLoS One. 2023;18(2):e0280753.
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  

footer